Phase two study to evaluate carboplatin and vincristine as second line therapy in management of glioblastoma multiform versus bevacizumab

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511863395261

Enrollment

120

Registered

2025-11-14

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Carboplatin and vincristine cycle

Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Known by pathology or MRS;(Magnetic Resonance Spectroscopy) GBM. - Failed or progressed or recurrent or refractory upon 1st line treatment. - 24 hr Creatinine clearance > 30 ml/min. - Performance status 0-3

Exclusion criteria

Exclusion criteria: - platinum anaphylaxis or sensitivity. - Performance status 4. - 24 hr Creatinine clearance < 30 ml/min

Design outcomes

Primary

Measure	Time frame
response rate Response categories: CR (Complete Response) Disappearance of all target lesions. Lymph nodes must shrink to <10 mm short axis. PR (Partial Response) =30% decrease in the sum of diameters of target lesions from baseline. SD (Stable Disease) Neither sufficient shrinkage (to qualify for PR) nor sufficient increase (for PD).	—

Secondary

Measure	Time frame
Progression Free Survival (PFS): it measures the time from the start of treatment until: The tumor shows signs of progression (based on imaging).	—

Countries

Egypt

Contacts

Public ContactEsraa Mahmoud Mohamed Abdelmawla

residant doctor at Clinical oncology department Assiut university

Esraa.17310036@med.aun.edu.eg+201094667210

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026